MediWound (MDWD) Misses Q2 EPS by 8c, Revenues Miss
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 7/6/2026
- US stock futures up as chip shares recover, oil prices decline
- Oil falls after OPEC+ agrees to raise output targets
- Dow jumps to record closing high after soft US jobs data, Nasdaq down with chip shares
- Goldman's Garrett sees investors dialing back tech exposure into H2
- AI chip winners may face tougher road ahead as hyperscalers catch up: JPM
MediWound Reports Second Quarter 2020 Financial Results and Provides Corporate Update
August 6, 2020 7:01 AM EDTSubmitted Biological License Application to the FDA for NexoBridÂ
EscharEx U.S. Phase 2 Study Resumed Patient Screening
YAVNE, Israel, Aug. 06, 2020 (GLOBE NEWSWIRE) -- MediWound Ltd. (Nasdaq: MDWD) (the Company), a fully-integrated biopharmaceutical company bringing innovative therapies to address unmet needs in severe burn and wound management, today announced financial results for the second quarter ended June 30, 2020 and provided business and financial updates related to the COVID-19 pandemic.Â
Second Quarter Business and Financial Highlights:
Revenues for the second quarter of 2020 were $4.0... More